News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Seegene, Inc. to Feature Extended Mutation Detection Technology for Companion Diagnostics at American Association for Clinical Chemistry 2013


6/24/2013 10:23:34 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GAITHERSBURG, MARYLAND and SEOUL, KOREA--(Marketwired - June 24, 2013) - Seegene Inc., (KOSDAQ: 096530), a leading developer of multiplex molecular diagnostic technologies and tests, today announced it would be unveiling its multiple mutation detection technology to accelerate the development of companion diagnostic (CDx) tests at the 2013 American Association of Clinical Chemistry (AACC) annual meeting, held in Houston, from July 30 - August 1.

A major benefit of this technology is that it successfully transforms existing, conventional real-time instruments into powerful systems for simultaneous detection of multiple mutation targets in a single channel. Seegene has now extended the capabilities of its real-time PCR technology to simultaneously detect more than 20 different mutations, including insertions, deletions, and point mutations, in a single tube and single reaction.

"The extended capability of real-time PCR for mutation detection is a natural progression of our technology. The ability to detect and differentiate mutations is critical, but the ability to detect those mutations without any wild-type signal on current real-time instrumentation is a significant advancement in molecular diagnostics, and in particular companion diagnostics," said Dr. Jong-Yoon Chun, founder, CTO and CEO of Seegene.

Key features of this technology include:

  • Detection of minority mutation or species when wild-type is in excess of 10,000 fold higher (0.01%)
  • Robust chemistry across the wide-range of annealing temperature (50-65 degrees C)
  • Elimination of wild-type signal even at high concentration of wild-type DNA (~1000 ng) in an assay

Dr. Chun added, "We want to make the technology widely available on the market. We believe that this mutation detection technology has the potential to strengthen the businesses of traditional diagnostic companies, and 'wake up' a large portion of the market to new opportunities. That is why we are initiating an aggressive licensing and OEM campaign to make this technology broadly available."

To set up a meeting with Seegene and learn more about mutation detection technology send an email to jasonbae@seegene.com

Or visit Seegene at booth 3115 at AACC in Houston July 30th - August 1st, 2013.

About Seegene
Seegene is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies -- ACP™, DPO™, READ, and TOCE™ -- are the foundation for multiplex molecular diagnostics and companion diagnostic tests that can simultaneously detect, differentiate, detect minority species and quantitate multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene's mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.

For more information please visit www.seegene.com or call +82-2-2240-4081.


Contacts:
Jason Bae, Ph.D.
Seegene Inc.
+82-2-2240-4081
Email Contact

or

Constantine Theodoropulos
Base Pair Group
617-816-4637
Email Contact



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES